Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

The high prevalence of injecting drug use among affected patients prompted some authors to conclude that concurrent heroin nephropathy, not HIV-1 infection per se, was responsible for this renal syndrome. As a result, HIV-associated nephropathy (HIVAN) became recognized as a separate entity and soon was found to be the most common cause of chronic renal failure and end stage renal disease (ESRD) in HIV-1 infected patients [5,6]. Despite the presence of proteinuria that is often in the nephrotic range, most patients with HIVAN do not have significant peripheral edema [15]. These observations, coupled with the finding that HIV-seropositive patients often have a decreased ability to conserve sodium [17] suggest that HIVAN may be a salt-wasting disease. Serologic studies are usually negative although a significant percentage of HIV-1 seropositive patients are co-infected with hepatitis C virus (HCV) [18]. Since firmly establishing the diagnosis of HIVAN versus a different renal disease is important to guide treatment and provides prognostic information, clinicians should have a low threshold for obtaining renal biopsies in HIV-1-seropositive patients with significant proteinuria and/or renal insufficiency. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the US Government.As a result of the decline in mortality from AIDS, however, the number of black patients who are living with HIV infection or AIDS has increased dramatically (Fig. 3) [23]. Though this study did not specify the types of renal disease, the presence of renal disease was disproportionately higher in black (11.9%) compared to white patients (3.3%), suggesting that a this difference (8.6%) may reflect underlying HIVAN. Recently, published data from the HIV Epidemiology Research Study Group revealed that among HIV-1 seropositive women (without AIDS), 7.2% had renal abnormalities (defined as serum creatinine > 1.4 mg/dl or > 2+ proteinuria on urinary dipstick) at baseline. Furthermore, after adjusting for multiple comorbidities, the presence of renal disease was with a increased risk of death While the of HIVAN has been studied in the it is to be most in the more than living with HIV/AIDS nearly in the prevalence of HIVAN among is similar to that among African there are and cases of HIVAN in this Despite these however, there is a of published data the of HIVAN in for These include a of a fai

Key findings

Why it matters

This article describes HIV-associated nephropathy, a kidney disease in people with HIV, and does not address Alzheimer's disease at all. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record left out, no data; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 45 of the 97 points it could be judged on, which is 46 of 100. Total 46 of 100.45 of the 97 points we could judge = 46 of 100

Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 45 of the 97 points we could judge it on, which is 46 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (AIDS)
Journal's citation record 3 / 4 AIDS: journal h-index 267 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2004 — older than 20 years, still counted
Sample size 2 / 4 200 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 78 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.2 citations a year over 24 year(s) since 2004
Impact for its field and year 3 / 6 Cited 5.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Paul E. Klotman: h-index 65 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 15166524)
Free to read 0 / 2 Behind a paywall — scores zero
Points 45 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 97 points we could judge it on is 46 out of 100.
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Ross, M. J., & Klotman, P. E. (2004). HIV-associated nephropathy. AIDS. https://doi.org/10.1097/00002030-200405210-00002

Vancouver

Ross MJ, Klotman PE. HIV-associated nephropathy. AIDS. 2004. doi:10.1097/00002030-200405210-00002. PMID: 15166524.

BibTeX

@article{ross2004-15166524,
  author  = {Ross, Michael J. and Klotman, Paul E.},
  title   = {{HIV-associated nephropathy}},
  journal = {AIDS},
  year    = {2004},
  doi     = {10.1097/00002030-200405210-00002},
  pmid    = {15166524},
  url     = {https://doi.org/10.1097/00002030-200405210-00002}
}

Related studies in Risk factors

Similar studies

More on Risk factors

See all studies in Risk factors →